Educomunicación en los estudios de Máster de profesorado: Análisis de cinco universidades españolas

Treball Final del Màster Universitari en Noves Tendències i Processos d'Innovació en Comunicació (Pla 2016) . Codi: SBP052. Curs acadèmic 2021-2022El presente trabajo constituye una investigación sobre el estado madurativo de la educomunicación en las enseñanzas universitarias de Máster de Profesorado en cinco universidades españolas en la era post-COVID 19. Tras un breve repaso de los acontecimientos más destacados de nuestra actualidad, que motivan y justifican nuestro interés en este campo de estudio, se realiza una revisión de los hechos históricos más significativos que establecen los fundamentos de la educomunicación y sus distintos enfoques teóricos, hasta contextualizar el estado de la cuestión en nuestros días. La concepción metodológica de nuestra investigación es transversal y de alcance exploratorio, combinando técnicas cualitativas y cuantitativas en nuestra investigación a fin de dar respuesta a las hipótesis planteadas. La primera parte de esta investigación se centra en el análisis exploratorio y comparativo de los planes de estudios de dichas universidades. La segunda parte, recoge las reflexiones y percepciones de diversos expertos y docentes vinculado en el ámbito de estudio.This paperwork constitutes an investigation on the media literacy maturational state in five Spanish universities with regards to in the post-COVID 19 era. After a brief review of the most outstanding events of our present time, motivating and justifying our interest in this field of study, a review of the most significant historical facts that underpin the foundations of media literacy and its different theoretical approaches is carried out, leading to contextualization of the state of the question in our days. The methodological conception of our research is cross-sectional and exploratory in scope, combining qualitative and quantitative techniques in our research in order to respond to the hypotheses raised. The first part of this research is focused on the exploratory and comparative analysis of the curricula of these five universities. The second part is focused on collecting the reflections and perceptions of various experts and teachers on media literacy matters

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio